Migraine research trial seeks participants with chronic migraine and medication overuse headache

Adults with chronic migraine and medication overuse headache sought

Migraine researchers at the Royal Victoria Infirmary in Newcastle and King’s College London are currently recruiting adult patients with a documented history of migraine without aura and/or migraine with aura and medication overuse headache (MOH).

About the study

If you choose to participate and meet the study requirements, you will be in this study for approximately 59 weeks. The 59-week period consists of an up to seven week screening period and a 52-week treatment period.

During the treatment period you will be randomised (shuffled) into one of the three groups; placebo, or one of the two doses of study medicinal product being studied for the first 24 weeks of the study. Neither you nor the study doctor nor the study staff will know which product you are receiving (study product or placebo) during the first 24 weeks of the study. This is called the double-blind treatment period (DBTP). In an emergency, the study doctor can find out what you are receiving.

For the next 28 weeks of the study, you, the study doctor, and the study staff will know that you are receiving one of the two doses of the study product. This is called the open-label treatment period (OLTP).

If you would like to take part

If you would like to find out more or take part in this trial, please contact one of the below centres depending on your location.

Please note: Before doing this, we advise that you speak to your GP regarding the study.

  • Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, under Dr William Sedley. Contact email: william.sedley@nhs.net
  • Kings College London, London, under Prof Peter Goadsby. Contact email: headache-research@kcl.ac.uk
  • Hull Royal Infirmary, Hull, under Prof Fayyaz Ahmed. Contact email: fayyaz.ahmed@nhs.net

In line with ABPI Code of Practice this is a non-promotional material, which is being used for a clinical trial.